Everything you care about in one place
Follow feeds: blogs, news, RSS and more. An effortless way to read and digest content of your choice.
Get Feederfiercebiotech.com
FierceBiotech
Get the latest updates from FierceBiotech directly as they happen.
Follow now 344 followers
Latest posts
Last updated about 12 hours ago
Lundbeck to move US digs to Boston as it eyes bigger innovation frontiers
about 12 hours ago
With Lundbeck steering its R&D engine toward increasingly specialized neuroscience targets, the...
Chutes & Ladders—Travere chief makes way for former Amicus CEO
about 14 hours ago
Travere Therapeutics CEO Eric Dube, Ph.D., is stepping down after overseeing the...
Pioneer of China NewCo model sued in US over trade secret misuse, double-dealing
about 14 hours ago
A legal feud unfolding in New York is putting a spotlight on...
Novo inks $1.3B Nanexa deal to unlock long-acting obesity injectables
about 16 hours ago
Novo has struck a 1.17 billion euro ($1.3 billion) deal to combine...
Indivior ends PAM drug collab with Addex ahead of Supernus merger
about 16 hours ago
Ahead of its upcoming merger with Supernus, Indivior Pharmaceuticals has ended its...
Roche's Genentech inks $1.5B bispecific pact with fast-rising Earendil
about 19 hours ago
Roche’s Genentech is paying Earendil Labs $55 million upfront to discover and...
ADARx scores upsized $446M IPO, while fellow RNA biotech City maps out Nasdaq plans
about 19 hours ago
ADARx Pharmaceuticals has overshot its own IPO ambitions, as fellow RNA-focused biotech...
New approach methodologies in safety and toxicology testing: Why proving repeatability is the next hurdle for widespread adoption
1 day ago
NAMs could transform drug safety testing—but proving repeatability and cell health remains...
Trump's FDA pick Heidi Overton calls vaccines, mifepristone safe and effective in confirmation hearing
1 day ago
The Senate Committee on Health, Education, Labor and Pensions (HELP) today questioned...
Acadia misses mark in Alzheimer’s but concludes phase 3 ‘absolutely worth’ pursuing
1 day ago
Acadia Pharmaceuticals’ phase 2 Alzheimer’s disease trial has missed its primary endpoint...
China’s Henlius carves out $440M T-cell engager deal with Amberstone
1 day ago
Fosun Pharma subsidiary Henlius Biotech has signed a $440 million biobucks deal...
Grail survives adcomm vote as it awaits FDA decision for cancer blood test
1 day ago
Despite a major trial setback earlier this year and increasing questions over...